LabCorp (LH)
Stock Price Chart
Key Info
| Market Cap | 18.41B |
| Revenue (ttm) | 11.47B |
| Net Income (ttm) | 362.20M |
| Shares Out | 97.40M |
| EPS (ttm) | 3.71 |
| PE Ratio | 50.96 |
| Forward PE | 17.04 |
| Dividend | n/a |
| Dividend Yield | n/a |
Stock Quote
| Trading Day | Aug 14, 2020 |
| Last Price | $189.05 |
| Previous Close | $190.59 |
| Change ($) | -1.54 |
| Change (%) | -0.81% |
| Day's Open | 190.41 |
| Day's Range | 188.48 - 191.12 |
| Day's Volume | 167,383 |
| 52-Week Range | 98.02 - 206.74 |
More Stats
| Market Cap | 18.41B |
| Enterprise Value | 24.97B |
| Earnings Date (est) | Oct 21, 2020 |
| Ex-Dividend Date | n/a |
| Shares Outstanding | 97.40M |
| Float | 96.83M |
| EPS (basic) | 3.71 |
| EPS (diluted) | 3.71 |
| FCF / Share | 12.08 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Earnings Yield | 1.96% |
| FCF Yield | 6.38% |
| Payout Ratio | n/a |
| Shares Short | 1.43M |
| Short Ratio | 1.72 |
| Short % of Float | 1.67% |
| Beta | 1.41 |
| PE Ratio | 50.96 |
| Forward PE | 17.04 |
| P/FCF Ratio | 15.68 |
| PS Ratio | 1.60 |
| PB Ratio | 2.47 |
| Revenue | 11.47B |
| Operating Income | 781.40M |
| Net Income | 362.20M |
| Free Cash Flow | 1.17B |
| Net Cash | -6.56B |
| Net Cash / Share | -67.32 |
| Gross Margin | 28.35% |
| Operating Margin | 6.81% |
| Profit Margin | 3.20% |
| FCF Margin | 10.23% |
| ROA | 4.65% |
| ROE | 4.99% |
| ROIC | n/a |
Analyst Summary
Analyst Consensus: Buy
Financial Performance
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 11,555 | 11,333 | 10,308 | 9,553 | 8,680 | 6,012 | 5,808 | 5,671 | 5,542 | 5,004 |
| Revenue Growth | 1.95% | 9.95% | 7.9% | 10.06% | 44.39% | 3.5% | 2.41% | 2.33% | 10.76% | - |
| Gross Profit | 3,253 | 3,176 | 3,092 | 2,854 | 2,903 | 2,203 | 2,223 | 2,250 | 2,275 | 2,098 |
| Operating Income | 1,330 | 1,326 | 1,305 | 1,271 | 997 | 904 | 991 | 1,024 | 948 | 979 |
| Net Income | 824 | 884 | 1,227 | 712 | 438 | 511 | 574 | 583 | 520 | 558 |
| Shares Outstanding | 97.10 | 101 | 102 | 103 | 101 | 84.50 | 87.40 | 94.60 | 99.10 | 102 |
| Earnings Per Share | 8.35 | 8.61 | 11.81 | 6.82 | 4.35 | 5.91 | 6.25 | 5.99 | 5.11 | 5.29 |
| EPS Growth | -3.02% | -27.1% | 73.17% | 56.78% | -26.4% | -5.44% | 4.34% | 17.22% | -3.4% | - |
| Operating Cash Flow | 1,445 | 1,305 | 1,498 | 1,197 | 982 | 739 | 819 | 841 | 856 | 884 |
| Capital Expenditures | -400 | -380 | -313 | -279 | -256 | -204 | -202 | -174 | -146 | -126 |
| Free Cash Flow | 1,045 | 926 | 1,185 | 918 | 727 | 536 | 617 | 668 | 710 | 758 |
| Cash & Equivalents | 338 | 427 | 317 | 434 | 716 | 580 | 404 | 467 | 159 | 231 |
| Total Debt | 7,108 | 6,060 | 6,762 | 5,850 | 6,364 | 3,030 | 3,000 | 2,655 | 2,221 | 2,188 |
| Net Cash / Debt | -6,770 | -5,633 | -6,446 | -5,416 | -5,648 | -2,450 | -2,596 | -2,188 | -2,062 | -1,958 |
| Assets | 18,046 | 16,185 | 16,673 | 14,247 | 14,105 | 7,302 | 6,966 | 6,795 | 6,112 | 6,188 |
| Liabilities | 10,459 | 9,195 | 9,848 | 8,726 | 9,145 | 4,464 | 4,455 | 4,057 | 3,588 | 3,701 |
| Book Value | 7,567 | 6,971 | 6,804 | 5,506 | 4,945 | 2,821 | 2,491 | 2,717 | 2,504 | 2,466 |
Company Profile
Company Details
| Full Name | LabCorp |
| Country | United States |
| Employees | 65,000 |
| CEO | Adam H. Schechter |
Stock Information
| Ticker Symbol | LH |
| Stock Exchange | New York Stock Exchange |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Unique Identifier | NYSE: LH |
Description
Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It operates in two segments, LabCorp Diagnostics (LCD) and Covance Drug Development. It offers various clinical laboratory tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C and vitamin D products, prostate-specific antigens, tests for sexually-transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. The company also provides testing services in the areas of women's health, allergy, diagnostic genetics, cardiovascular and infectious disease, endocrinology, oncology, coagulation, pharmacogenetics, toxicology, and medical drug monitoring; and esoteric testing, cancer diagnostics, and other procedures. In addition, it provides a suite of applications to enable patients, healthcare providers, health systems, accountable care organizations, and insurers with access to LCD's data and services, as well as billing for laboratory services. Further, it offers end-to-end drug development, medical device, and diagnostic development solutions from research to clinical development and commercial market access. The company primarily serves managed care organizations, biopharmaceutical companies, physicians and other healthcare providers, hospitals and health systems, governmental agencies, employers, patients and consumers, contract research organizations, academic institutions, and independent clinical laboratories. Laboratory Corporation of America Holdings has collaborations with the Boston University, Columbia University, Duke University, Johns Hopkins University, The Mount Sinai Hospital, the University of Tennessee, Yale University, and QIAGEN N.V; and Ciox Health for the creation of COVID-19 patient data registry in the United States. The company was founded in 1971 and is headquartered in Burlington, North Carolina.